Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024
Data highlights potential of Hummingbird Bioscience’s dual-payload antibody-drug conjugate platform to improve upon the current generation of ADCs SAN FRANCISCO and SINGAPORE, May 13, 2024 (Korea Bizwire) – Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced two presentations at the 20th Annual PEGS Boston summit being held from [...]










